The finding that IL-13 release was also inhibited by levalbuterol (Figure 9) is of interest because IL-13 is one of the cytokines that is central to cellular trafficking; blocking its ligands is a feature of dupilumab in the treatment of chronic obstructive pulmonary disease (COPD) and other eosinophilic disorders [59,62]. This evidence concerns the gene IL13 and eosinophil disorder.